menu
    • menu

    Company profile for NeoImmuneTech

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    NeoImmuneTech, Inc. (NIT) is a biotech company developing T cell-centered novel immunotherapeutics. NIT Pioneers Next Generation Cancer Immunotherapeutics Technology: NIT’s lead product is Hyleukin-7(TM*), an engineered T cell amplifier designed to reconstitute and enhance antitumoral T cell immunity. Hyleukin-7(TM) consists of homodimeric Interleukin-7 (IL-7) molecules, which are homeostatic cytokines that enhance the numbe...
    NeoImmuneTech, Inc. (NIT) is a biotech company developing T cell-centered novel immunotherapeutics. NIT Pioneers Next Generation Cancer Immunotherapeutics Technology: NIT’s lead product is Hyleukin-7(TM*), an engineered T cell amplifier designed to reconstitute and enhance antitumoral T cell immunity. Hyleukin-7(TM) consists of homodimeric Interleukin-7 (IL-7) molecules, which are homeostatic cytokines that enhance the number and function of T cells, biologically fused to IgD/IgG4 immunoglobulin domain (hyFc®) as a safe and effective long-acting carrier.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NeoImmuneTechUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2400 Research Blvd., Suite 250, Rockville, MD 20850
    Telephone
    Telephone
    240-801-9068
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://neoimmunetech.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/neoimmunetech
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NeoImmuneTech Presents CAR-T Combo Data With NT-I7 At ESMO 2024
    NeoImmuneTech Presents CAR-T Combo Data With NT-I7 At ESMO 2024

    09 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neoimmunetech-presents-promising-interim-results-of-car-t-combination-with-its-nt-i7-asset-at-esmo-2024-302241828.html

    PR NEWSWIRE
    09 Sep 2024
    Share Share
    NeoImmuneTech: EMA Orphan Drug For NT-I7 In Acute Radiation Syndrome
    NeoImmuneTech: EMA Orphan Drug For NT-I7 In Acute Radiation Syndrome

    04 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ema-grants-orphan-drug-designation-to-neoimmunetechs-nt-i7-for-the-treatment-of-acute-radiation-syndrome-302163015.html

    PR NEWSWIRE
    04 Jun 2024
    Share Share
    NeoImmuneTech's NT-I7 Plus CPI Combo Benefits In Immuno-Oncology
    NeoImmuneTech's NT-I7 Plus CPI Combo Benefits In Immuno-Oncology

    03 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neoimmunetechs-new-data-at-asco-2024-highlights-enhanced-benefits-of-combining-nt-i7-with-checkpoint-inhibitors-cpi-in-immuno-oncology-302161746.html

    PR NEWSWIRE
    03 Jun 2024
    Share Share
    NeoImmuneTech's NT-I7 + Chemo Effective In Colorectal Cancer
    NeoImmuneTech's NT-I7 + Chemo Effective In Colorectal Cancer

    09 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neoimmunetechs-nt-i7-in-combination-with-chemotherapy-shows-efficacy-in-colorectal-cancer-at-aacr-meeting-302111608.html

    PR NEWSWIRE
    09 Apr 2024
    Share Share
    NeoImmuneTech Appoints Dr. Luke Oh, Ph.D. as New Chief Executive Officer
    NeoImmuneTech Appoints Dr. Luke Oh, Ph.D. as New Chief Executive Officer

    02 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neoimmunetech-appoints-dr-luke-oh-phd-as-new-chief-executive-officer-302105682.html

    PR NEWSWIRE
    02 Apr 2024
    Share Share
    FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech's NT-I7
    FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech's NT-I7

    30 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-grants-orphan-drug-designation-odd-status-to-neoimmunetechs-nt-i7-for-advanced-pancreatic-cancer-treatment-302047851.html

    PR NEWSWIRE
    30 Jan 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search